Open AccessFocal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study
Author(s) -
William Yaxley,
Troy Gianduzzo,
Boon Kua,
Rachel Oxford,
John Yaxley
Publication year - 2022
Publication title -
investigative and clinical urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.653
H-Index - 14
eISSN - 2466-054X
pISSN - 2466-0493
DOI - 10.4111/icu.20210472
Subject(s) - medicine , irreversible electroporation , prostate cancer , prostate , prostatectomy , biopsy , urology , biochemical recurrence , cancer , prostate specific antigen , radiology , biochemistry , chemistry , electroporation , gene
Focal irreversible electroporation (IRE) for prostate cancer aims to reduce quality of life complications, however outcomes data remains limited. We aimed to evaluate histological in-field clearance of prostate cancer at ≥12 months post-IRE.